Neurocrine to acquire Soleno in $2.9 billion all-cash deal
Neurocrine Biosciences said it has agreed to buy Soleno Therapeutics for $53 per share in cash, a transaction that would add Soleno’s VYKAT XR to Neurocrine’s endocrinology and rare-disease portfolio. The companies said both boards approved the deal on April […]
Neurocrine to acquire Soleno in $2.9 billion all-cash deal Read More »










